But the story doesnt end with skin
Aaron Boster about GLP-1 receptor agonists and whether theyre a good idea for people with MS
Reviews published in 2025 describe a body of research dominated by animal and cell studies, with signals suggesting effects on angiogenesis (the growth of blood vessels), growth-factor signalling (mainly growth hormone) and musculoskeletal healing
Wei S, Zhang J, Guan H, et al
Tapering is critical, says Niazi
We only succeed when employers and their employees do, too. To mark the announcement of these new products, which will be available in January, Noom also published a whitepaper today Breaking the GLP-1 Cost Cycle: Transforming Access, Cutting Costs, and Shaping the Future of Obesity Care